Publications by authors named "Schaeverbeke T"
Objectives: To evaluate the effectiveness of short message service (SMS) and/or email reminders in improving influenza vaccination coverage rates among rheumatoid arthritis (RA) patients treated with anti-TNF therapies, and to identify factors associated with vaccination.
Methods: A nested randomized controlled trial in the ART e-cohort, an ongoing French nationwide multicentre prospective cohort of RA patients treated with anti-TNF therapy. Patients were 1:1 randomized, with stratification on age.
Introduction: Immune checkpoint inhibitors-induced inflammatory arthritis (ICI-IA) affects about 5% of ICI recipients. We aimed (1) to characterize the resolution of ICI-IA during ICI treatment and after ICI discontinuation and (2) to assess how ICI-IA influences ICI management across time.
Methods: All ICI-treated patients referred to rheumatology at Bordeaux University Hospital were identified and patients with ICI-IA with a follow-up of≥6months after ICI-IA onset were included.
Objective: Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety of ICI rechallenge in this setting. We aimed to assess the rate and clinical features associated with ICI-IA flare/recurrence on ICI rechallenge.
Methods: We conducted a multicentre observational study including cancer patients with ICI-IA who started a second course of ICI more than 3 months after ICI discontinuation in four French university hospitals.
Objective: We assess the clinical and structural impact at two years of progressively spacing tocilizumab (TCZ) or abatacept (ABA) injections versus maintenance at full dose in patients with rheumatoid arthritis in sustained remission.
Methods: This multicenter open-label noninferiority (NI) randomized clinical trial included patients with established rheumatoid arthritis in sustained remission receiving ABA or TCZ at a stable dose. Patients were randomized to treatment maintenance (M) at full dose (M-arm) or progressive injection spacing (S) driven by the Disease Activity Score in 28 joints every 3 months up to biologics discontinuation (S-arm).
Objectives: To investigate whether the efficacy and safety data from drug-registration trials can be extrapolated to real-life RA patients receiving RTX.
Methods: The 'AutoImmunity and Rituximab' (AIR-PR) registry is a French multicentre, prospective cohort of RA patients treated with RTX in a real-life setting. We compared treatment responses at 12 months and serious adverse events (AEs) between eligible and non-eligible patients, by retrieving the eligibility criteria of the three rituximab-registration trials.
Article Synopsis
- The study investigates the effect of JAK inhibitors (JAKis) on patients with monoclonal gammopathy of undetermined significance (MGUS) who also have active rheumatic diseases.
- Researchers identified 20 patients, primarily with rheumatoid arthritis, receiving JAKis like baricitinib and tofacitinib for an average of 15.5 months.
- Results showed that nearly half of the patients experienced a decrease in serum monoclonal protein levels, suggesting that JAKis may have a positive impact on MGUS in individuals with rheumatic conditions.
Article Synopsis
- Lumacaftor-ivacaftor is a CFTR modulator combination effective for cystic fibrosis patients with the F508del allele, showing improvement in clinical outcomes like body mass index and fewer antibiotic courses.
- A study involving 75 patients analyzed changes in airway microbiota, mycobiota, and inflammation markers before and after 6 months of treatment; overall, no significant changes in microbial diversity or inflammation were found.
- However, patients not chronically colonized with Pseudomonas aeruginosa showed decreased inflammation and increased bacterial diversity, suggesting individual patient characteristics influence treatment outcomes.
Introduction: Clinical and immunological features of patients with cancer-associated systemic sclerosis: an observational study.
Objective: Several studies have reported an increased incidence of cancer in patients with systemic sclerosis (SSc). The presence of RNA polymerase III antibodies (anti-RNA Pol 3) associates with an increased risk of cancer, but other risk factors need yet to be identified.
Objectives: To investigate whether meticulously following a treat-to-target (T2T)-strategy in daily clinical practice will lead to less radiographic progression in patients with active RA who start (new) DMARD-therapy.
Methods: Patients with RA from 10 countries starting/changing conventional synthetic or biologic DMARDs because of active RA, and in whom treatment intensification according to the T2T principle was pursued, were assessed for disease activity every 3 months for 2 years (RA-BIODAM cohort). The primary outcome was the change in Sharp-van der Heijde (SvdH) score, assessed every 6 months.
Purpose: JAK-inhibitors (JAK-i) might be associated with venous (VTE) and arterial thromboembolic events (ATE). To evaluate the association between JAK-i and the risk of VTE and ATE.
Methods: A self-controlled case series was performed using data from the nationwide French healthcare insurance system database SNDS.
Objective: There is limited experience regarding the use of biological disease-modifying antirheumatic drug (bDMARD) and JAK inhibitor (JAKi) for the management of immune checkpoint inhibitors (ICI)-induced inflammatory arthritis. We aimed to assess their efficacy and safety in this setting.
Methods: Using the Club Rhumatismes and Inflammation French network, we conducted a multicentre, retrospective, observational study of patients with cancer diagnosed with inflammatory arthritis under ICI(s) and treated with bDMARD or JAKi.
Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors.
Cancer Immunol Immunother
November 2022
Background: To investigate the evolution of bone metastases in patients receiving immune checkpoint inhibitors (ICI).
Methods: A single-center retrospective study included cancer patients with bone metastases treated with ICI at our institution between January 2014 and September 2019. Clinical and biological data were collected from medical records and independent expert review of imaging was performed.
Objective: To characterize the role of interleukin-1β (IL-1β) and microvascular endothelial cells (MVECs) in the generation of alternatively activated macrophages in the skin, and to explore their role in the development of skin fibrosis in patients with systemic sclerosis (SSc; scleroderma).
Methods: Conditioned medium prepared with MVECs purified from the skin of healthy donors and the skin of SSc patients was used to generate monocyte-derived macrophages. Flow cytometry, multiplex protein assessment, real-time quantitative polymerase chain reaction, and tissue immunofluorescence were used to characterize MVEC-induced polarization of alternatively activated macrophages.
Purpose: As gut microbiota composition is an important determinant of response to immune checkpoint inhibitors (ICIs), we examined the effect of various co-medications known for their interaction with microbiota, when given at ICI initiation.
Patients And Methods: We identified patients with advanced cancer treated with ICI between May 2015 and September 2017 in our institution. Co-medications given within 1 month before or 1 month after the first administration of ICI were reviewed from medical records.
Background: The major risk factor for idiopathic pulmonary fibrosis (IPF), MUC5B rs35705950, was found to be associated with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Whilst the MUC5B rs35705950 T risk allele has been associated with better survival in IPF, its impact on RA-ILD prognosis remains to be determined. Our objective was to explore the influence of MUC5B rs35705950 on survival and progression in RA-ILD.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare the effectiveness of biological reference agents like infliximab, etanercept, and adalimumab in rheumatoid arthritis (RA) using patients from trials that either compared these agents to a placebo or to a biosimilar.
- Researchers analyzed data from 31 randomized controlled trials and found a better response (ACR 20/50) when these agents were compared to biosimilars than to placebos, indicating a 70% response rate in the biosimilar group versus 59% in the placebo group.
- The results suggest that the reference agent's superior performance when compared to biosimilars might be due to a stronger placebo effect in active trials or a nocebo effect in trials
Objective: Innate lymphoid cells-2 (ILC2) were shown to be involved in the development of lung or hepatic fibrosis. We sought to explore the functional and phenotypic heterogeneity of ILC2 in skin fibrosis within systemic sclerosis (SSc).
Methods: Blood samples and skin biopsies from healthy donor or patients with SSc were analysed by immunostaining techniques.
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by a loss of tolerance toward self-nucleic acids, autoantibody production, interferon expression and signaling, and a defect in the regulatory T (T) cell compartment. In this work, we identified that platelets from patients with active SLE preferentially interacted with T cells via the P-selectin/P-selectin glycoprotein ligand-1 (PSGL-1) axis. Selectin interaction with PSGL-1 blocked the regulatory and suppressive properties of T cells and particularly follicular T cells by triggering Syk phosphorylation and an increase in intracytosolic calcium.
View Article and Find Full Text PDFObjective: To compare the risk of diverticulitis and gastrointestinal perforation (GIP) in RA treated with tocilizumab (TCZ) compared with rituximab (RTX) and abatacept (ABA).
Methods: We conducted a population-based study using three observational French registries on TCZ, RTX and ABA in RA. Using a propensity score approach, we compared the risk of diverticulitis or GIP in these patients.
Article Synopsis
- * At the 10-year mark, a significant portion of patients achieved various forms of remission, with 52.4% in DAS28 remission and only 6.5% requiring major joint surgery, indicating a mild overall outcome.
- * The findings suggest that the current patient cohort had better outcomes compared to older cohorts, likely due to more intensive treatment approaches available in recent years.
Objective: The Flare Assessment in RA (FLARE-RA) self-administered questionnaire aims to identify patients who had flare in the interval between two consultations. This study aimed to establish a threshold for FLARE-RA score to identify RA flare.
Methods: The Tocilizumab SubCutAneous study evaluated the efficacy and safety of s.